Background

The results from Gynecologic Oncology Group protocol 240, that blockade and non-platinum chemotherapy, predictive biomarkers are
requichemotherapy plus bevacizumab significantly improves overall survival over chemotherapy alone among women with advanced cervical cancer, represents a proof of concept of the potential for anti-angiogenesis therapy and the value of systemic therapy in this disease. To identify patients likely to derive the greatest benefit from angiogenesis red and predicated on theranostics, the emerging field through which developing technologies and capabilities in the diagnostic sector can be applied to pharmacogenomics and personalized medicine.